Novartis’ Pluvicto Gains Expanded FDA Approval for Prostate Cancer Treatment
Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that it has received expanded indication approval from...
EMA’s CHMP Issues Negative Opinion on Lilly’s Kisunla for Alzheimer’s
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
China’s IAC Drafts Commercial Health Insurance Drug List A-Series to Bridge NRDL Coverage Gaps
The Insurance Association of China (IAC) has unveiled its inaugural draft for the Commercial Health...
China Scraps Outpatient Prepayment in Public Hospitals by 2025: Healthcare Reform Shifts Financial Burden
The National Health Commission (NHC) will eliminate outpatient prepayment requirements across public medical institutions by...
uBriGene Appoints Dr. Joy Zhou to Lead Cell Therapy Development
China-based advanced therapy medicinal product (ATMP) contract development and manufacturing organization (CDMO) uBriGene Biosciences announced...
BMS’s Opdivo/Yervoy Combo Approved by NMPA for First-Line HCC Treatment
Bristol-Myers Squibb (BMS, NYSE: BMY) announced that it has received approval from China’s National Medical...
Roche’s Ocrevus Approved by China’s NMPA for Multiple Sclerosis Treatment
Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced that it has received marketing approval...
Shanghai Bio-heart Launches SAKURA-SCB Study for Drug-Coated Balloon in Japan
China-based Shanghai Bio-heart Biological Technology Co., Ltd (HKG: 2185) announced the first patient enrollment for...
AstraZeneca’s Imfinzi Approved by FDA for Bladder Cancer Treatment
The US Food and Drug Administration (FDA) has approved AstraZeneca’s (NASDAQ: AZN) PD-L1 inhibitor Imfinzi...
MicroPort Endovascular Reports 1.61% Revenue Growth in 2024 with Strong Profit Increase
Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016) released its 2024 financial report, showing a...
Luye Pharma Group Reports 2024 Revenue Dip Despite Growth in Product Sales
China-based Luye Pharma Group (HKG: 2186) announced its 2024 financial performance, recording RMB 6.061 billion...
Hengrui Pharmaceuticals Reports 22.63% Revenue Growth in 2024 with Strong Innovative Drug Sales
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) released its 2024 financial report, recording RMB...
Sanofi’s Qfitlia Approved by FDA for Hemophilia A and B Prophylaxis
France-based Sanofi (EPA: SAN, NASDAQ: SNY) has announced receiving marketing approval from the US Food...
Brii Biosciences Presents Elebsiran Phase II Data at APASL 2025 Meeting
China-based Brii Biosciences Ltd (HKG: 2137) has published the latest data from its ongoing Phase...
Akeso Biopharma Reports 53% Revenue Decline in 2024 Despite Growth in Product Sales
China-based Akeso Biopharma (HKG: 9926) released its 2024 financial report, recording RMB 2.124 billion (USD...
IASO Biotherapeutics’ Fucaso Approved in Macao for Relapsed Multiple Myeloma
China-based IASO Biotherapeutics announced that the New Drug Application (NDA) for its BCMA-targeted chimeric antigen...
Eli Lilly Launches Kisunla in China for Early Alzheimer’s Treatment
US pharmaceutical giant Eli Lilly and Company (NYSE: LLY) has officially launched Kisunla (donanemab) in...
Laekna Submits Revised Protocol for LAE102 Obesity Trial with Eli Lilly
Sino-US biotech Laekna Therapeutics (HKG: 2105) announced the submission of a revised clinical protocol to...
Apollomics Partners with LaunXP for Vebreltinib in Asian NSCLC Treatment
Apollomics Inc. announced on March 31, 2025, a strategic development and commercialization agreement with Taiwan-based...
Bioray Biopharmaceutical Expands to Turkey with Three Key Drugs, Marking International Milestone
Zhejiang Bioray Biopharmaceutical Co., Ltd. announced on March 31 that it has reached a collaboration...